Winway Health Desk
The Adderall Shortage in the US: Implications for ADHD Treatment
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects many individuals, particularly children and adolescents. One of the most common medications used...
How Blue Cross NC Is Using Its Hybrid Work Model to...
Due to Covid-19, many companies moved to a hybrid work model, leading to their buildings being largely underutilized. Blue Cross and Blue Shield of...
U.S. FDA Approves ALK’s Odactra (House Dust Mite Allergen Extract) Tablet...
Odactra is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in persons 12 through 17 years of age,...
FDA Approves Keytruda (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and...
Approval based on KEYNOTE-091 trial, which demonstrated a clinically meaningful improvement in disease-free survival with KEYTRUDA in these patients following surgical resection and platinum-based...
U.S. FDA Approves Takeda’s Takhzyro (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE)...
Takhzyro is the First and Only Prophylaxis Treatment Approved in the U.S. for Children 2 to <6 Years of Age With HAE1-4
Approval Supported by...
FDA Approves Syfovre (pegcetacoplan injection) for the Treatment of Geographic Atrophy,...
FDA Approves Syfovre (pegcetacoplan injection) for the Treatment of Geographic Atrophy, a Leading Cause of BlindnessWALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis...
U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least...
Eylea (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm...
TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Grants Accelerated Approval to Filspari (sparsentan) for the Reduction of...
FDA Grants Accelerated Approval to Filspari (sparsentan) for the Reduction of Proteinuria in IgA NephropathyFirst single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved...
FDA Approves Pfizer’s Supplemental New Drug Application for Cibinqo (abrocitinib) to...
Label expansion for Cibinqo provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
NEW YORK--(BUSINESS WIRE) February 10, 2023...
